Capstone Investment Advisors
SRPT icon

Capstone Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Capstone Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-6,000
Closed -$452K – 1451
2019
Q3 		$452K Buy
+6,000
New +$709K ﹤0.01% 1112

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Capstone Investment Advisors's SRPT Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 15,681 shares worth $282K. The stake represents ﹤0.01% of the portfolio and ranks #1482 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in SRPT as recently as Q3 2025.

Capstone Investment Advisors first reported a position in SRPT in Q2 2013 and has held it in 5 quarters since. The position peaked at $1.27M in Q1 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Capstone Investment Advisors held 15,681 shares of Sarepta Therapeutics worth $282K as of Q2 2026.
  • Sarepta Therapeutics was a new Capstone Investment Advisors position in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1482 holding.
  • Capstone Investment Advisors first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 5 quarters since.
  • Capstone Investment Advisors's Sarepta Therapeutics position peaked at $1.27M in Q1 2025.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.